Literature DB >> 2961716

Interaction of interstitial photodynamic therapy and interstitial hyperthermia in a rat rhabdomyosarcoma--a pilot study.

P C Levendag1, H P Marijnissen, V J de Ru, J A Versteeg, G C van Rhoon, W M Star.   

Abstract

Photodynamic therapy (PDT) involves the activation of photosensitizing drugs by light of appropriate wavelength. The photosensitive agent Hematoporphyrin Derivative (HPD) appears to be preferentially retained in malignant tumors; irradiation of HPD-containing tissue by light of appropriate wavelength (625 nm) and dose leads to (tumor) tissue destruction. The aim of this study is to achieve maximum tumor control probability with minimum normal tissue photosensitivity. In previous work from our laboratory it has been demonstrated that PDT has its fundamental effects on the tumor and normal tissue microcirculation. As it is well established that hyperthermia (HT) has its major effects in less well vascularized areas of the tumor, the combined modality of HT and PDT might prove to be advantageous. Moreover, suppression of sublethal damage repair by HT has been observed. To overcome the problem of poor light penetration into tissues and the high rate of recurrences following PDT with external irradiation, the combined effects of interstitial PDT with interstitial hyperthermia in a new line of animal experiments were studied in our laboratory. An experimental murine tumor (Rhabdomyosarcoma, type R-1) was transplanted in WAG/Rij rats and, after reaching an average diameter of 2 cm, the active component of HPD, that is Photofrin II, was injected intravenously in different dose schedules (5 mg/kg, 10 mg/kg). After 24 or 48 hrs the tumors were implanted with four flexible catheters, through which either light or heat could be applied. Light was obtained from an Argon-Dye laser system tuned to a wavelength of 625 nm at a dose rate of 75-100 mW per fiber to a dose level of 900 Joule from four linear light applicators. Heat (44 degrees C/30') was delivered by four 27 MHz radiofrequency antennas. Dose response relationships for PDT alone, HT alone and PDT combined with HT were established with cure as endpoint. This study showed that these two modalities, in the proper sequence and spacing, result in an augmented cytotoxicity on the tumor cells in vivo. With the combined modality treatment a cure rate of 41% (90 days) was obtained. As the implantation of flexible catheters is a well-known technique in radiation therapy practice, the potentiating effects of interstitial HT combined with interstitial PDT in solid tumors is very promising and clinical studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2961716     DOI: 10.1016/0360-3016(88)90061-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Photodynamic therapy.

Authors:  T J Dougherty; C J Gomer; B W Henderson; G Jori; D Kessel; M Korbelik; J Moan; Q Peng
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

2.  Vascular function and tissue injury in murine skin following hyperthermia and photodynamic therapy, alone and in combination.

Authors:  J V Moore; C M West; A K Haylett
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

3.  Interstitial photodynamic therapy. Clinical experience with diffusing fibres in the treatment of cutaneous and subcutaneous tumours.

Authors:  C P Lowdell; D V Ash; I Driver; S B Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

4.  Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment.

Authors:  D K Kelleher; O Thews; A Scherz; Y Salomon; P Vaupel
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

5.  Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours.

Authors:  D K Kelleher; J Bastian; O Thews; P Vaupel
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.